Key result
Prostaglandin E administration is linked to an unusual migratory polycyclic eruption in a neonate.
Why the study?
Alprostadil (PGE1) is used to maintain a patent ductus arteriosus in neonates with ductal-dependent congenital heart disease, but its adverse events profile requires further characterization.
Does alprostadil administration cause unusual migratory polycyclic eruptions in neonates with congenital heart disease?
Case Report (n=1)
Does alprostadil administration cause unusual migratory polycyclic eruptions in neonates with congenital heart disease?
Highlights a rare dermatological adverse event (migratory polycyclic eruption) associated with alprostadil use in a neonate with congenital heart disease.
PGE1-induced migratory polycyclic eruptions merit recognition in neonates on alprostadil; leaves open incidence and risk factors in larger cohorts.
Alprostadil is a prostaglandin E1 analogue (PGE1 α-cyclodextrin clathrate) used in neonates to maintain a patent ductus arteriosus in cases of ductal-dependent congenital heart disease (CHD).1 PGE1 is critical in sustaining oxygen saturation in these patients while awaiting surgical repair or cardiac transplant. Despite being reasonably well tolerated, a review of 62 neonates with CHD treated with PGE1 suggested a range of adverse events, most commonly including central nervous system events (16%), respiratory depression (12%), and cardiovascular complications (18%).
No takes yet. Share an insight, caveat, or question.
Young et al. (2016) conducted a case report in ductal-dependent congenital heart disease (CHD) (n=1). prostaglandin E1 (Alprostadil) was evaluated. Administration of prostaglandin E in a neonate was associated with an unusual migratory polycyclic eruption.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: